98 related articles for article (PubMed ID: 8656838)
1. [Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?].
Zachrisson O; Lindefors N
Lakartidningen; 1996 Mar; 93(13):1225-7. PubMed ID: 8656838
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
Reubi JC; Schaer JC; Waser B
Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors.
Tirassa P; Stenfors C; Lundeberg T; Aloe L
Br J Pharmacol; 1998 Mar; 123(6):1230-6. PubMed ID: 9559909
[TBL] [Abstract][Full Text] [Related]
5. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
6. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
Schmitz F; Pratt DS; Wu MJ; Kolakowski LF; Beinborn M; Kopin AS
Mol Pharmacol; 1996 Aug; 50(2):436-41. PubMed ID: 8700154
[TBL] [Abstract][Full Text] [Related]
7. [Psychopharmaceuticals as instruments for research].
Vinar O
Cesk Psychiatr; 1988 Feb; 84(1):28-35. PubMed ID: 2896551
[No Abstract] [Full Text] [Related]
8. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of 5-membered ring-type compounds as potential cholecystokinin receptor ligands.
Pentassuglia G; Araldi GL; Donati D; Feriani A; Oliosi B; Pasquarello A; Ursini A
Farmaco; 1997 Oct; 52(10):573-81. PubMed ID: 9507668
[TBL] [Abstract][Full Text] [Related]
10. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
[TBL] [Abstract][Full Text] [Related]
11. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
Harro J
Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.
Schatzberg AF; Lindley S
Eur J Pharmacol; 2008 Apr; 583(2-3):358-64. PubMed ID: 18339372
[TBL] [Abstract][Full Text] [Related]
13. CCK receptors in human neuroendocrine tumors: clinical implications.
Reubi JC
Scand J Clin Lab Invest Suppl; 2001; 234():101-4. PubMed ID: 11713969
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of the FGF system in psychiatric disorders.
Riva MA; Molteni R; Bedogni F; Racagni G; Fumagalli F
Trends Pharmacol Sci; 2005 May; 26(5):228-31. PubMed ID: 15860368
[TBL] [Abstract][Full Text] [Related]
15. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
[TBL] [Abstract][Full Text] [Related]
16. CCK-X receptors in the endothermic mako shark (Isurus oxyrinchus).
Oliver AS; Vigna SR
Gen Comp Endocrinol; 1996 Apr; 102(1):61-73. PubMed ID: 8860310
[TBL] [Abstract][Full Text] [Related]
17. Decreased haloperidol-induced potentiation of zif268 mRNA expression in the nucleus accumbens shell and the dorsal lateral striatum of rats lacking cholecystokinin-A receptors.
Shilling PD; Feifel D
Synapse; 2002 Feb; 43(2):134-8. PubMed ID: 11754493
[TBL] [Abstract][Full Text] [Related]
18. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
19. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M; Liu G; Pinon DI; Miller LJ
Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
[TBL] [Abstract][Full Text] [Related]
20. CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis).
Oliver AS; Vigna SR
Gen Comp Endocrinol; 1997 Jan; 105(1):91-101. PubMed ID: 9000471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
